The pancreatic cancer research described in this release is preclinical, which may not be predictive of clinical outcomes. The Company is currently planning to sponsor an investigator initiated ...

Physician-led healthcare company connects patients through the Inviah mobile app with credentialed doctors on demand, making medical care more accessible and convenient. CHICAGO, ...

Results of the study will be shared by Dr. Misha Rosenbach, MD, in an oral presentation at ACR Convergence 2026 today, November 10 ...

The newly issued patent covers medical devices and methods for capturing and processing physiological signals through advanced sensing and processing circuitry. The technology enables signal ...

Patients and clinicians across Ontario are calling for clarity about the future of OHIP-funded chronic pain treatment. Save Pain Clinics, an advocacy campaign bringing together patients, caregivers, ...

Low disease activity (LDA) rates increased from 57.1% to 65.1% in the continuous ianalumab monthly group between Weeks 48 and 108. In patients who switched from placebo to ianalumab monthly at Week 60 ...

CHRISTUS Health's advancement from Level 8 to Level 9 demonstrates meaningful progress in its ongoing digital transformation journey and its commitment to responsible innovation.

Reporting to President and Chief Executive Officer John M. Starcher, Jr., Baker will lead ministry-wide philanthropic efforts to advance BSMH’s mission and strengthen access to affordable, quality ...

Orphan Drug Designation, granted in July 2026, provides development incentives to support Senza5 CART5 in T-cell lymphoma ...

Multiple research studies have shown that consuming a whole food, plant-based diet can lead to weight loss similar to that seen with semaglutide and improve insulin sensitivity, reduce inflammation, ...

Eighty-five postoperative shoulder patients were enrolled, consisting of 27 anatomic total shoulder arthroplasties (aTSA) and 58 reverse total shoulder arthroplasties (rTSA). The authors report that ...

Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced ...